XWELL, Inc. Reports Third Quarter 2024 Results
XWELL Inc reported Q3 2024 results with revenue growth of 13% year-over-year to $8.4 million. The company demonstrated cost reduction initiatives, reducing total operating expenses by 35% for the nine-month period. Revenue primarily came from XpresSpa locations ($4.9M) and XpresTest ($3.1M). The company maintains a strong financial position with $4.4M in cash and $11.7M in marketable securities. Operating loss was $4.8M compared to $12.1M in Q3 2023. XWELL completed a registered direct offering in August 2024, raising $1.4M in gross proceeds.
XWELL Inc ha riportato i risultati del terzo trimestre del 2024 con una crescita dei ricavi del 13% rispetto all'anno precedente, raggiungendo i 8,4 milioni di dollari. L'azienda ha dimostrato iniziative di riduzione dei costi, diminuendo le spese operative totali del 35% per il periodo di nove mesi. I ricavi sono provenuti principalmente dalle sedi di XpresSpa (4,9 milioni di dollari) e XpresTest (3,1 milioni di dollari). L'azienda mantiene una solida posizione finanziaria con 4,4 milioni di dollari in contante e 11,7 milioni di dollari in titoli negoziabili. La perdita operativa è stata di 4,8 milioni di dollari rispetto ai 12,1 milioni di dollari del terzo trimestre del 2023. XWELL ha completato un'offerta diretta registrata nell'agosto del 2024, raccogliendo 1,4 milioni di dollari in proventi lordi.
XWELL Inc informó los resultados del tercer trimestre de 2024 con un crecimiento de ingresos del 13% interanual, alcanzando los 8,4 millones de dólares. La empresa demostró iniciativas de reducción de costos, disminuyendo los gastos operativos totales en un 35% durante el período de nueve meses. Los ingresos provinieron principalmente de las ubicaciones de XpresSpa (4,9 millones de dólares) y XpresTest (3,1 millones de dólares). La compañía mantiene una sólida posición financiera con 4,4 millones de dólares en efectivo y 11,7 millones de dólares en valores negociables. La pérdida operativa fue de 4,8 millones de dólares en comparación con 12,1 millones de dólares en el tercer trimestre de 2023. XWELL completó una oferta directa registrada en agosto de 2024, recaudando 1,4 millones de dólares en ingresos brutos.
XWELL Inc는 2024년 3분기 실적을 발표하며 매출이 전년 대비 13% 증가하여 840만 달러에 달했다고 밝혔습니다. 회사는 비용 절감 이니셔티브를 통해 9개월 동안 총 운영 비용을 35% 줄였습니다. 매출은 주로 XpresSpa 지점에서 490만 달러, XpresTest에서 310만 달러를 기록했습니다. 회사는 현금 440만 달러와 시장성 있는 증권 1170만 달러로 강력한 재무 상태를 유지하고 있습니다. 운영 손실은 480만 달러로, 2023년 3분기의 1210만 달러에 비해 감소했습니다. XWELL은 2024년 8월에 등록된 직접 제공을 완료하며 140만 달러의 총 수익을 올렸습니다.
XWELL Inc a rapporté des résultats pour le troisième trimestre 2024 avec une croissance du chiffre d'affaires de 13 % par rapport à l'année précédente, atteignant 8,4 millions de dollars. L'entreprise a mis en œuvre des initiatives de réduction des coûts, réduisant les dépenses opérationnelles totales de 35 % sur une période de neuf mois. Le chiffre d'affaires provient principalement des emplacements XpresSpa (4,9 M$) et XpresTest (3,1 M$). L'entreprise maintient une situation financière solide avec 4,4 millions de dollars en liquidités et 11,7 millions de dollars en titres négociables. La perte opérationnelle s'élevait à 4,8 millions de dollars par rapport à 12,1 millions de dollars au troisième trimestre 2023. XWELL a complété une offre directe enregistrée en août 2024, levant 1,4 million de dollars en produits bruts.
XWELL Inc berichtete über die Ergebnisse des dritten Quartals 2024 mit einem Umsatzwachstum von 13% im Jahresvergleich auf 8,4 Millionen Dollar. Das Unternehmen zeigte Initiativen zur Kostenreduzierung und senkte die gesamten Betriebsausgaben in den letzten neun Monaten um 35%. Der Umsatz kam hauptsächlich aus XpresSpa Standorten (4,9 Millionen Dollar) und XpresTest (3,1 Millionen Dollar). Das Unternehmen hält eine starke Finanzlage mit 4,4 Millionen Dollar in bar und 11,7 Millionen Dollar in veräußerten Wertpapieren. Der operative Verlust betrug 4,8 Millionen Dollar im Vergleich zu 12,1 Millionen Dollar im dritten Quartal 2023. XWELL schloss im August 2024 eine registrierte Direktplatzierung ab und erzielte Bruttoeinnahmen von 1,4 Millionen Dollar.
- Revenue growth of 13% YoY in Q3 2024
- Cost of sales reduced by 6% for nine-month period
- Total operating expenses reduced by 35% YoY for nine-month period
- G&A expenses reduced by 5% for nine-month period
- Strong liquidity position with $16.1M in cash and marketable securities
- Operating loss of $4.8M in Q3 2024
- Net loss of $4.8M in Q3 2024
- Increased G&A expenses to $4.5M in Q3 2024 vs $3.0M in Q3 2023
- Higher salaries and benefits at $1.9M vs $1.2M in Q3 2023
- Share dilution from $1.4M registered direct offering
Insights
XWELL's Q3 2024 results show mixed signals. While revenue grew
The company's liquidity position remains stable with
The company's strategic pivot shows promise but faces challenges. The expansion beyond airports through Naples Wax Center and the planned Penn Station location represents a significant opportunity to capture new customer segments. However, the core XpresSpa business with 29 global locations still drives the majority of revenue at
The biosurveillance business through XpresCheck contributed
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), an authority in wellness solutions for people on the go, today reported results for the third quarter and nine-month period ended September 30, 2024.
Recent Highlights:
- XWELL delivered 2024 third quarter revenue growth of approximately
13% from the comparable quarter in 2023. Additionally, for the nine-month period ended September 30, 2024, XWELL delivered revenue growth of approximately16% from the comparable nine-month period in 2023. - XWELL continues to focus on reducing its cost structure and returning to profitability. For the nine-month period ended September 30, 2024, the Company:
- Reduced cost of sales by approximately
6% when compared with the comparable nine-month period in 2023. - Reduced general and administrative expenses by approximately
5% when compared with the comparable nine-month period in 2023. - Reduced total operating expenses by approximately
35% when compared with the comparable nine-month period in 2023.
- Reduced cost of sales by approximately
- In August of 2024, XWELL continued to fuel its future growth plans by executing a registered direct offering resulting in gross proceeds of
$1.4 million , which was priced at a premium to market.
“We're pleased with our third quarter and year-to-date performance, marked by the successful implementation of growth and productivity initiatives across our organization,” said Ezra Ernst, CEO of XWELL. “As we focus on achieving healthy, sustainable growth and returning to profitability, we're seeing considerable opportunities across all of our brands. Looking forward, we believe we're well-positioned for a strong 2025, and we remain confident that our consistent strategy execution will benefit our customers, partners, employees, and shareholders.”
Travel Wellness Portfolio - XpresSpa®
XpresSpa is the leading airport retailer of wellness services and related products. As of September 30, 2024, there were 19 domestic XpresSpa locations and 10 international locations operating, including two XpresSpa locations in Dubai International Airport in the United Arab Emirates, one XpresSpa location in Zayad International Airport in Abu Dhabi, United Arab Emirates, three XpresSpa locations in Schiphol Amsterdam Airport in the Netherlands and four XpresSpa locations in the Istanbul Airport in Turkey.
As previously announced, XpresSpa opened a new location in Philadelphia International Airport (PHL) during the 2024 second quarter. Located in Terminal B near Gate B2, the PHL XpresSpa includes the Company’s new branding as well as innovative offerings including its new Ceragem therapeutic massage and compression beds, Clockwork MiNiCURE and Human Touch automated massages.
Out-of-Airport Wellness Portfolio - Naples Wax Center®
XWELL’s first off-airport brand, Naples Wax Center, is a group of upscale hair removal and aesthetic services boutiques with three locations in Florida. Acquired in mid-September 2023, Naples Wax Center provides core products and service including face and body waxing as well as a range of skincare and cosmetic products from its current three locations.
The Company is in the process of executing additional leases in Florida, forecasting approximately 10 XWELL out-of-airport locations in 2025.
New York City’s Penn Station XpresSpa
Consistent with XWELL’s strategy to extend its footprint into transportation hubs, the Company is executing plans to open an XpresSpa location in New York City’s Penn Station in 2025.
The labor-lite, tech-forward spa will serve commuters, neighborhood locals, and tourists with wellness-focused retail, autonomous massage, and nail care services, enabling seamless and efficient experiences for time-crunched New York City travelers.
Life Sciences & Biosurveillance -- XpresCheck® and HyperPointe™
The Company’s XpresTest, Inc. subsidiary (“XpresCheck”), in collaboration with the Centers for Disease Control and Prevention (“CDC”) and Ginkgo Bioworks, currently operates 7 biosurveillance stations in 6 of the nation’s busiest airports.
XpresTest, Inc. began conducting bio surveillance monitoring with the Centers for Disease Control and Prevention (CDC) in collaboration with Concentric by Ginkgo BioWorks in 2021. The CDC's Traveler-based Genomic Surveillance (TGS) program is a flexible, multimodal platform that consists of complementary approaches of sample collection from arriving international travelers at U.S. airports, including voluntary nasal swabbing, aircraft wastewater, air monitoring and airport wastewater sampling to enhance early detection of new SARS-CoV-2 variants and other pathogens, and fill gaps in global surveillance.
Additionally, the Company began reporting operating results for HyperPointe within its XpresCheck business. Beginning in June 2020, and following its acquisition by XWELL in January 2022, HyperPointe’s management team and suite of services and technology have been utilized to develop and deploy the technological infrastructure necessary to scale the growth of the XpresCheck business. HyperPointe’s experience in this space continues to play a critical role in the expansion of ongoing biosurveillance efforts created in partnership with Ginkgo BioWorks and the CDC.
Liquidity and Financial Condition
As of September 30, 2024, the Company had approximately
On August 8, 2024, the Company closed its registered direct offering priced at a premium to market for the issuance and sale of an aggregate of 652,705 shares of its common stock, par value
Summary Third Quarter 2024 Financial Results
Revenue
Total revenue for the third quarter ended September 30, 2024, was
Revenue for the 2024 third quarter primarily consisted of approximately
Total Cost of Sales
Total cost of sales for the 2024 third quarter was approximately
Salaries and Benefits; General and Administrative Expenses
Salaries and benefits were approximately
General and administrative expenses were approximately
Total Operating Expenses
Total operating expenses were approximately
Operating Loss
The operating loss was approximately
Net Loss Attributable to XWELL
Net loss attributable to XWELL was approximately
Webcast and Earnings Conference Call
XWELL will host a webcast and conference call at 5:00 pm Eastern Time today. We encourage investors and all interested parties to listen via webcast as there is a limited capacity to access the conference call by dialing 1-412-317-6026.
The live and later archived webcast can be accessed from the Investor Relations section of the Company’s website at http://xwell.com. Visitors to the website should select the “Investors” tab and navigate to the “Events” link to access the webcast.
About XWELL, Inc.
XWELL, Inc. (Nasdaq: XWEL) is a leading global wellness holding company operating multiple brands: XpresSpa®, Treat™, Naples Wax Center®, XpresCheck® and HyperPointe™.
- XpresSpa is a leading retailer of wellness services and related products.
- Naples Wax Center is a group of upscale skin care boutiques.
- XpresCheck, in partnership with the CDC and Concentric by Ginkgo, conducts biosurveillance monitoring in its airport locations to identify new SARS-CoV-2 variants of interest and concern as well as other pathogens entering the country from across the world.
- HyperPointe is a leading digital healthcare and data analytics relationship company serving the global healthcare industry.
Forward-Looking Statements
This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. Forward-looking statements relating to expectations about future results or events, including the Company’s current plans and expectations relating to the business and operations and future store openings, including but not limited to, future openings of Naples Wax Center and XpresSpa stores, are based upon information available to XWELL as of the date of this press release, and are not guarantees of the future performance of the Company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in the Company’s Annual Report on Form 10-K, as amended, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XWELL, or other matters and attributable to XWELL or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XWELL does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.
Media
Maria Kucinski
MWW
mkucinski@mww.com
FAQ
What was XWELL's (XWEL) revenue growth in Q3 2024?
How much did XWELL (XWEL) reduce its operating expenses in 2024?
What was XWELL's (XWEL) operating loss in Q3 2024?
How much cash does XWELL (XWEL) have as of September 30, 2024?
